IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – What’s Next?

IPSEN (OTCMKTS:IPSEY) saw unusually-strong trading volume on Friday . Approximately 7,390 shares were traded during trading, an increase of 117% from the previous session’s volume of 3,412 shares.The stock last traded at $45.84 and had previously closed at $44.1425.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on IPSEY. BNP Paribas Exane lowered IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Monday, November 3rd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

IPSEN Price Performance

The stock’s 50-day moving average price is $37.80 and its two-hundred day moving average price is $35.54.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).